Blocks the malate / aspartate cycle by inhibiting glutamate - oxaloacetate transaminase (GOT ).
Blocks the malate / aspartate cycle by inhibiting glutamate - oxaloacetate transaminase (GOT).
Elevated bilirubin, alanine transaminase and lactate dehydrogenase concentrations are indicative of hepatocellular injury.
In Phase III RESIST trials, the frequency of transaminase elevations was significantly increased in the APTIVUS/ritonavir arm compared to the comparator arm.
In the majority of cases, liver transaminase levels have returned to their baseline value without the need for treatment discontinuation.
It may account for up to 90% of isolated increases of plasma transaminase of otherwise unknown cause.
Laboratory findings included acid urine despite alkali therapy and elevated serum transaminase activities.
The majority of transaminase elevations were of Grade 1-3 toxicity and resolved upon discontinuation of treatment.
These transaminase increases were likely to be related to the skeletal muscle effects.